U.S. Patent and Trademark Office; U.S. DEPART MENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Ou	ner: Monogram Biosciences, Inc.			
Application No /Pate	nt No.: 09/874,475 / 7,097,970	Filed/Issue Date: 06/04/2001 / 08/29/2006		
Titled: METHODS OF EVALUATING VIRAL ENTRY INHIBITORS USING PATIENT DERIVED ENVELOPE PROTEIN CONSTRUCTS				
Monogram Bioso	iences, Inc. , a	corporation		
(Name of Assignee)		(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.		
states that it is:				
1. X the assig	nee of the entire right, title, and interest in	in;		
2. an assig (The ext	nee of less than the entire right, title, and ent (by percentage) of its ownership inter-	l interest in rest is%); or		
3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)				
the patent application/patent identified above, by virtue of either:				
A.				
OR				
B. X A chain		application/patent identified above, to the current assignee as follows:		
1. From		To: Virologic, Inc.		
		ited States Patent and Trademark Office at $_{0}$ 0683, or for which a copy thereof is attached.		
2. From	Virologic, Inc.	To: SDS Merchant Fund, L.P.		
		ited States Patent and Trademark Office at		
	Reel 013599 , Frame	e0791 or for which a copy thereof is attached.		
3. Fron	SDS Merchant Fund, L.P.	To: Virologic, Inc.		
	The document was recorded in the Unit	ited States Patent and Trademark Office at		
	Reel 014066 , Frame	e 0810 or for which a copy thereof is attached.		
Additional documents in the chain of title are listed on a supplemental sheet(s).				
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.				
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]				
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.				
Signature				
Charles W. Calkins (Reg. No. 31,814)		Attorney for Applicant		
Printed or Typed Name Title				

This collection of information is requised by 57 CFR 3.73(b). The information is equived to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Condeniantly be pervised by 58 US, 61.22 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including application, provided the condeniant application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time provided the complete deposition for the complete deposition for the complete deposition for the CFR 1.21 and 1.14. This complete deposition for the CFR 1.21 and 1.14. This complete deposition for the CFR 1.21 and 1.2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Managram Biosciences Inc				
Applicant/Patent Owner: Monogram Biosciences, Inc.	5% df Dete: 06/04/2001 / 08/29/2006			
Application No./Patent No.: 09/874,475 / 7,097,970 Filed/Issue Date: 06/04/2001 / 08/29/2006				
Titled: METHODS OF EVALUATING VIRAL ENTRY INHIBITORS USING PATIENT DERIVED ENVELOPE PROTEIN CONSTRUCTS				
Monogram Biosciences, Inc. , a corpora				
(Name of Assignee) (Type of A	assignee, e.g., corporation, partnership, university, government agency, etc.			
states that it is:				
1. X the assignee of the entire right, title, and interest in;				
an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is				
3.				
the patent application/patent identified above, by virtue of either:				
An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy therefore is attached.				
OR				
B. X A chain of title from the inventor(s), of the patent application				
From: Aclara Biosciences, Inc.	To: Apollo Merger Subsidiary, LLC			
The document was recorded in the United States Reel 022825 Frame 0988	Patent and Trademark Office at, or for which a copy thereof is attached.			
2. From: Apollo Merger Subsidiary, LLC	To: Virologic, Inc.			
The document was recorded in the United States Reel 022827 , Frame 0166	Patent and Trademark Office at, or for which a copy thereof is attached.			
3. From: Virologic, Inc.	To: Monogram Biosciences, Inc.			
The document was recorded in the United States				
	or for which a copy thereof is attached.			
Additional documents in the chain of title are listed on a supplemental sheet(s).				
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.				
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]				
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.				
Signature	Date			
Charles W. Calkins (Reg. No. 31,814) Attorney for Applicant				
Printed or Typed Name	Title			

This collection of information is required by 97 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is giverned by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 Public which is to file (and by the USPTO to process) an application. Confidentially is giverned by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 Public which is to estimate to complete, including again entire to the confidential public to the complete application from to the USPTO. This well vary depending upon the individual case. Any outered not he amount of time you require to complete, including this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce P.O. (bit of VEA) Alexandriq V.S. 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriq, V.A. 22313-1450.

Under the Papervork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)				
Applicant/Patent Owner: Monogram Biosciences, Inc.				
Application No./Patent No.: 09/874,475 / 7,097,970 Filed/Issue Date: 06/04/2001 / 08/29	9/2006			
Titled: METHODS OF EVALUATING VIRAL ENTRY INHIBITORS USING PATIENT DERIVED ENVELOPE PROTEIN CONSTRUCTS				
Monogram Biosciences, Inc, acorporation				
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, gov	vernment agency, etc.			
states that it is:				
1.				
an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is				
3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)				
the patent application/patent identified above, by virtue of either:				
An assignment from the inventor(s) of the patent application/patent identified above. The assignment the United States Patent and Trademark Office at Reel, Frame	t was recorded in , or for which a			
B. X A chain of title from the inventor(s), of the patent application/patent identified above, to the current ass	signee as follows:			
1. From: Monogram Biosciences, Inc. To: Pfizer Inc.				
The document was recorded in the United States Patent and Trademark Office at Reel 017681 , Frame 0183 , or for which a copy therec	of is attached.			
2. From: Monogram Biosciences, Inc. To: Pfizer Inc.				
The document was recorded in the United States Patent and Trademark Office at Reel 017682 , Frame 0142 , or for which a copy therec	of is attached.			
3. From: Monogram Biosciences, Inc. To: Merrill Lynch Capital,				
The document was recorded in the United States Patent and Trademark Office at				
Reel 020325 Frame 0763 or for which a copy thereo	of is attached.			
Additional documents in the chain of title are listed on a supplemental sheet(s).				
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.				
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]				
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.				
Signature Date				
Charles W. Calkins (Reg. No. 31,814) Attorney for Applicant				
Printed or Typed Name Title	e			

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including agentering, preparing, and submitting the completed application from the USPTO. Three will vary depending upon the individual case. Any communication on the insurance of the processing of the individual case. Any communication of the individual case and the individual case. Any communication of the individual case and the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of the individual case. Any communication case is a communication of t for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

CTATEMENT LINDED 37 CED 3 73(b)

OTATEMEN	0112211			
Applicant/Patent Owner: Monogram Biosciences, Inc.				
Application No./Patent No.: 09/874,475 / 7,097,970	Filed/Issue Date: 06/04/2001 / 08/29/2006			
Titled: METHODS OF EVALUATING VIRAL ENTRY INHIBITORS USING PATIENT DERIVED ENVELOPE PROTEIN CONSTRUCTS				
Monogram Biosciences, Inc, acorporation				
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.				
states that it is:				
1. X the assignee of the entire right, title, and interest	in;			
2. an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is				
3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)				
the patent application/patent identified above, by virtue of either:				
An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy therefore is attached.				
OR				
	application/patent identified above, to the current assignee as follows:			
From: GE Business Financial Services	Inc., To: Monogram Biosciences, Inc.			
The document was recorded in the United States Patent and Trademark Office at Reel 023148, Frame 0723, or for which a copy thereof is attached.				
2. From:	То:			
The document was recorded in the Un	ited States Patent and Trademark Office at			
Reel, Fram	e, or for which a copy thereof is attached.			
3. From:	To:			
The document was recorded in the Un	ited States Patent and Trademark Office at			
Reel, Fram	e, or for which a copy thereof is attached.			
Additional documents in the chain of title are listed on a supplemental sheet(s).				
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.				
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]				
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.				
Signature Date				
Charles W. Calkins (Reg. No. 31,814) Attorney for Applicant				
Printed or Typed Name	Title			

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 things of the process) and application of the completed application from the USPTO. Time will vary depending upon the includious case. Any comments on the amount of time by the public work of the process of the public work of the process o